IMA

ImageneBio Inc

4.24

Oct 09 • 3:59 PM ET -0.02 (-0.47%)

4.24

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: ANVS EXOZ FBIO ICCC MCRB OSTX PLRX PMVP XBIT FLNA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	48.13M
Enterprise Value	-83.55M
Income	-53.33M
Sales	0.00M
Book/sh	12.60
Cash/sh	11.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Mar 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.34
P/C	0.35
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	21.47
Current Ratio	21.47
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-5.20
EPS next Y	-3.48
EPS next Q	-0.80
EPS this Y	66.60%
EPS next Y	-8.00%
EPS next 5Y	27.01%
EPS past 3/5Y	24.93% 8.22%
Sales past 3/5Y	-62.86% -38.64%
EPS Y/Y TTM	31.98%
Sales Y/Y TTM	-100.00%
EPS Q/Q	8.47%
Sales Q/Q	-
Earnings	Aug 05 BMO
EPS/Sales Surpr.	38.24% -

Insider Own	36.07%
Insider Trans	-0.08%
Inst Own	34.10%
Inst Trans	3.56%
ROA	-37.73%
ROE	-40.69%
ROIC	-36.29%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.82%
SMA50	-17.61%
SMA200	-27.10%
Trades

Shs Outstand	11.28M
Shs Float	7.26M
Short Float	0.45%
Short Ratio	2.51
Short Interest	0.03M
52W High	9.10 -53.41%
52W Low	3.94 7.61%
Volatility	5.63% 5.07%
ATR (14)	0.25
RSI (14)	25.34
Beta	0.82
Rel Volume	0.62
Avg Volume	13.09K
Volume	8,121

Perf Week	-7.83%
Perf Month	-15.28%
Perf Quarter	-30.61%
Perf Half Y	-13.50%
Perf YTD	-38.55%
Perf Year	-48.48%
Perf 3Y	-90.94%
Perf 5Y	-97.27%
Perf 10Y	-
Recom	2.00
Target Price	18.00
Prev Close	4.26
Price	4.24
Change %	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-26	Initiated	H.C. Wainwright	Buy	$28
Nov-25-25	Resumed	Wedbush	Underperform	$2
Oct-24-25	Initiated	Leerink Partners	Outperform	$30

Oct-02-26 04:30PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-26 04:30PM	ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York (GlobeNewswire)
Aug-17-26 04:30PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-26 08:00AM	ImageneBio Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-07-26 07:00AM	ImageneBio Appoints Matt Robbins as General Counsel (GlobeNewswire)
04:30PM	Loading…
May-27-26 04:30PM	ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-07-26 04:05PM	ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update (GlobeNewswire) -10.49%
Apr-13-26 07:00AM	ImageneBio Announces $30 Million Private Placement (GlobeNewswire) +23.42%
Mar-17-26 04:30PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-26 08:00AM	ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update (GlobeNewswire)
Feb-26-26 08:00AM	ImageneBio to Participate in Leerink Global Healthcare Conference (GlobeNewswire)
Feb-10-26 07:00AM	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer (GlobeNewswire)
Nov-12-25 07:15AM	ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team (GlobeNewswire)
Nov-06-25 08:30AM	ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences (GlobeNewswire)
Aug-05-25 09:55AM	Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade (Zacks)
04:15PM	Loading…
Aug-01-25 04:15PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-25-25 11:00AM	Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million (GlobeNewswire)

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

CEO & DirectorDr. Kristin Yarema Ph.D.

CFOMs. Yanina Grant-Huerta

Chief Strategy & Operations OfficerDr. Kurinji Pandiyan Ph.D.

Chief Technical OfficerMs. Renuka Sivendran Ph.D.

General CounselMr. Matt Robbins J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yarema Kristin	Chief Executive Officer	Jul 25 '26	Option Exercise	0.00	38,376	0	123,776	Jul 28 04:05 PM
Lally Robert B	Principal Accounting Officer	Jul 16 '26	Sale	5.50	1,671	9,190	57,107	Jul 20 09:47 PM
Lally Robert B	Principal Accounting Officer	Jul 17 '26	Sale	5.34	1,525	8,144	55,582	Jul 20 09:47 PM
SLATTERY JOSEPH P	Director	Dec 24 '25	Buy	5.99	16,000	95,840	16,000	Dec 29 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMA

ImageneBio Inc

Upgrade your Finviz experience